Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13

NCT07256392 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT07256392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07256392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13
Lead sponsor
Celldex Therapeutics
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
November 25, 2025
Completion date
September 30, 2028
Enrollment
1,370 (estimated)
Sites
182

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria